Literature DB >> 9475328

A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.

P König1, J Poehler, G J Barbero.   

Abstract

This placebo-controlled study was designed to confirm a previously performed open label study that showed significant improvement in spirometry on maintenance therapy with albuterol for 1 year. In a double-blind, cross-over trial, albuterol (by metered dose inhaler) 180 microg b.i.d. or placebo were given for 6 months each. Spirometry was monitored at the start, and 3 and 6 months following initiation of each arm of the study. Peak expiratory flow rate (PEFR) was measured twice daily at home before and after study drug administration. Only patients with clinically detectable lung disease were enrolled. Twenty-one patients finished the study. All spirometric tests showed a significant improvement from start to end of the 6 month treatment with albuterol; there was no significant change on placebo. Forced vital capacity improved by 8.2% and forced expiratory volume in 1 s by 12.1% on albuterol therapy. Nevertheless, there was no significant difference between change on albuterol and change on placebo. Home measurements of PEFR showed a significant improvement of 4.7% on albuterol and a non-significant change of 2.0% on placebo from the first to the last week of treatment. None of the long-term improvements (spirometry or home PEFR) correlated with mean daily bronchodilation. For albuterol, the number of days of hospitalization was less than half that for patients on placebo (1.0/patient on albuterol versus 2.6 on placebo), but this did not reach statistical significance. These results suggest a beneficial effect from maintenance therapy with albuterol. Bronchodilation alone probably cannot explain the long-term benefits of albuterol, and other mechanisms may play a role. The lack of significant difference between change on albuterol and change on placebo is probably due to too small a number of patients in this study and lack of statistical power.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9475328     DOI: 10.1002/(sici)1099-0496(199801)25:1<32::aid-ppul3>3.0.co;2-q

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  Bronchodilators in cystic fibrosis.

Authors:  P L Brand
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 2.  Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome.

Authors:  Chad R Marion; Manuel Izquierdo; Holly C Hanes; Christopher Barrios
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

Review 3.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Chronic β2AR stimulation limits CFTR activation in human airway epithelia.

Authors:  John J Brewington; Jessica Backstrom; Amanda Feldman; Elizabeth L Kramer; Jessica D Moncivaiz; Alicia J Ostmann; Xiaoting Zhu; L Jason Lu; John P Clancy
Journal:  JCI Insight       Date:  2018-02-22

Review 5.  Short-acting inhaled bronchodilators for cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Christopher T Edwards
Journal:  Cochrane Database Syst Rev       Date:  2022-06-24

6.  Exhaled breath condensate detects baseline reductions in chloride and increases in response to albuterol in cystic fibrosis patients.

Authors:  Courtney M Wheatley; Wayne J Morgan; Nicholas A Cassuto; William T Foxx-Lupo; Cori L Daines; Mary A Morgan; Hanna Phan; Eric M Snyder
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.